[2]
Fruman, D.A.; Meyers, R.E.; Cantley, L.C. Phosphoinositide kinases. Annu. Rev. Biochem., 1998, 67, 481-507.
[3]
Fry, D.W.; Kraker, A.J.; McMichael, A.; Ambroso, L.A.; Nelson, J.M.; Leopold, W.R.; Connors, R.W.; Bridges, A.J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science, 1994, 265, 1093-1095.
[4]
Dar, A.C.; Shokat, K.M. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu. Rev. Biochem., 2011, 80, 769-795.
[5]
TurabNaqvi, A.A.; Hasan, G.M.; Hassan, M.I. Targeting tau hyperphosphorylation via kinase inhibition- Strategy to address Alzheimers’ disease. Curr. Top. Med. Chem., 2020, 20(12), 1059-1073.
[6]
Bheemanaboina, R.R.Y. Isoform-Selective PI3K Inhibitors for Various Diseases. Curr. Top. Med. Chem., 2020, 20(12), 1074-1092.
[7]
Gill, M.S.A.; Saleem, H.; Ahemad, N. Plant extracts and their secondary metabolites as modulators of kinases. Curr. Top. Med. Chem., 2020, 20(12), 1093-1104.
[8]
Kumar, M.; Joshi, G.; Chatterjee, J.; Kumar, R. Epidermal Growth Factor Receptor and its trafficking regulation by acetylation: Implication in resistance and exploring the newer therapeutic avenues in cancer. Curr. Top. Med. Chem., 2020, 20(12), 1105-1123.